Invenio Imaging
Invenio Imaging is a medical technology company specializing in rapid, non-destructive tissue imaging using Stimulated Raman Histology (SRH) and artificial intelligence. Their flagship product, the NIO Laser Imaging System, enables near real-time intraoperative imaging of fresh tissue samples without staining or sectioning, facilitating immediate feedback during surgeries. The company integrates AI-based image analysis to assist surgeons and pathologists in cancer detection, with CE-marked products in the EU and ongoing FDA breakthrough device designation processes in the US. Invenio Imaging serves surgical subspecialties including neurosurgery, pulmonology, urology, and oncology, and has achieved significant clinical adoption with over 2000 NIO systems used. Their technology supports digital image sharing via DICOM and allows specimen retrieval for downstream analysis, positioning them as a leader in intraoperative digital pathology and AI-assisted cancer diagnostics.
Invenio Imaging
Invenio Imaging is a medical technology company specializing in rapid, non-destructive tissue imaging using Stimulated Raman Histology (SRH) and artificial intelligence. Their flagship product, the NIO Laser Imaging System, enables near real-time intraoperative imaging of fresh tissue samples without staining or sectioning, facilitating immediate feedback during surgeries. The company integrates AI-based image analysis to assist surgeons and pathologists in cancer detection, with CE-marked products in the EU and ongoing FDA breakthrough device designation processes in the US. Invenio Imaging serves surgical subspecialties including neurosurgery, pulmonology, urology, and oncology, and has achieved significant clinical adoption with over 2000 NIO systems used. Their technology supports digital image sharing via DICOM and allows specimen retrieval for downstream analysis, positioning them as a leader in intraoperative digital pathology and AI-assisted cancer diagnostics.
TL;DR
Flagship product: NIO Laser Imaging System — SRH-based fresh-tissue imaging producing digital images in ~3 minutes without staining or sectioning
Use cases: Intraoperative tissue evaluation and AI-assisted cancer detection across neurosurgery, pulmonology, urology and oncology
Regulatory & adoption: CE-marked in the EU; FDA Breakthrough Device Designation announced Oct 30, 2024 for an AI image-analysis module; reported clinical deployment >2000 NIO systems
Founding & origin: Founded 2012 based on stimulated Raman histology (SRH) research emerging from Harvard